Project
This page treats policy landmarks as analytic eras rather than historical footnotes. The question is whether later eligible cohorts actually look cleaner once enough time has passed.
On registry-visible measures, the recent eligible era looks worse than the FDAAA 801 era.
A standalone E156 project comparing older CT.gov completion cohorts across pre-FDAAA, FDAAA, and later policy eras.
Across The Series
The split projects are meant to be read together because each isolates a different dimension of registry opacity rather than forcing every question into one leaderboard.
Industry-focused missing-results stock, sponsor backlogs, and structural sparsity inside CT.gov.
Sponsor-class comparisons on rate, stock, and structural hiddenness rather than one flattened ranking.
Phase-by-phase disclosure gaps showing how silence changes along the development pathway.
Field-level missingness across publication links, IPD statements, descriptions, and locations.
Results-plus-publication visibility states showing how many older trials are fully visible, partly visible, or ghosted.
Completion-era reporting debt showing how older eligible cohorts drift on no-results and ghost-protocol rates.
Keyword-classified therapeutic-area hiddenness mapping across common condition families.
Concentration and inequality analysis showing how much unresolved stock sits inside a thin sponsor slice.
Sample-based external PubMed NCT audit testing how often CT.gov no-link records hide an external paper trail.
Oncology-specific CT.gov hiddenness showing where cancer-trial stock, phases, and sponsors still go quiet.
Cardiovascular CT.gov hiddenness showing how heart and vascular studies remain quiet across major phases and sponsors.
Metabolic CT.gov hiddenness across obesity, diabetes, and related trial portfolios with large late-phase and NA stock.